Multibio

Quick links to important sections

Multibio

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Multibio

Quick Facts

Property Description
Active ingredients Ampicillin, Colistimethate Sodium, Dexamethasone
Form Sterile Suspension for Injection
Pharmacological class Triple Combination Antibacterial and Anti-inflammatory Agent
General purpose Simultaneous pathogen elimination and inflammation management
Origin Semi-synthetic and Natural-derived

Multibio is a specialized triple-combination pharmaceutical preparation strictly intended as a veterinary medicine, dispensed as a sterile suspension for injection. This Prescription Drug (RX) is uniquely positioned to deliver integrated therapeutic action, combining potent antibacterial efficacy with rapid anti-inflammatory effects, which is clinically recognized for managing acute conditions where both infection and inflammation are present.


Definition, Class, and Identity

Multibio is classified at a high level as an Antibacterial and Anti-inflammatory Agent, a designation reflecting its dual therapeutic function. It is a combination product because it simultaneously utilizes three distinct active compounds, differentiating it from single-agent drugs. The product's components have a mixed origin: Ampicillin and Dexamethasone are semi-synthetic derivatives, while Colistimethate Sodium is derived from naturally occurring polypeptides. This antibiotic is notable for being administered as an inactive precursor, known as a prodrug, which is then converted by the body into the active form, Colistin.


What Active Ingredients are in Multibio?

The formulation relies on three essential active ingredients: Ampicillin, Colistimethate Sodium (Colistin), and Dexamethasone. Ampicillin belongs to the aminopenicillin drug class, a classification that indicates its role in disrupting the structure of susceptible bacteria. Colistimethate Sodium is a polypeptide antibiotic that complements Ampicillin's action by targeting bacterial cell membranes. Dexamethasone is a potent glucocorticoid included to mediate acute physiological responses, limiting local swelling and discomfort. The specific nature of the Sterile Suspension for Injection form ensures the active components are carried in an aqueous or oily suspension base for effective parenteral route administration.


General Therapeutic Goal of the Triple Combination

The general therapeutic goal of this triple-combination approach is to achieve rapid, comprehensive stabilization in veterinary patients. In acute scenarios, the formulation provides a broad spectrum of microbial activity coupled with the immediate benefit of controlling the inflammatory cascade. This strategy ensures the elimination of the microbial cause and the mitigation of acute inflammatory pathology simultaneously.

Regulatory References

  1. Ampicillin - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Multibio?

Possible side effects and safety information

The official safety profile for Multibio, a combination product containing Ampicillin, Colistimethate Sodium, and Dexamethasone, is structured around adverse reactions categorized by System-Organ Class (SOC) as documented in regulatory sources.


Documented Adverse Reactions

The product's components contribute to distinct safety domains. The official labeling notes adverse effects across multiple systems, including Renal and Urinary Disorders (Nephrotoxicity from Colistimethate Sodium), Nervous System Disorders (Neurotoxicity, including slurred speech and paresthesia), and Gastrointestinal Disorders (diarrhea and the potential for ulceration).

Adverse Reaction Category Primary Concerns Officially Listed
Immune System Hypersensitivity reactions, including severe anaphylactic shock (Ampicillin component).
Endocrine System HPA axis suppression and the induction of Iatrogenic Hyperadrenocorticism (Cushing's-like symptoms) with the Dexamethasone component.
Respiratory System Risk of Respiratory Arrest/Apnea due to neuromuscular blockade (Colistimethate Sodium), particularly in the setting of renal impairment.

Safety Constraints and Considerations

Adverse reactions are formally classified by frequency; for the corticosteroid component, effects like Polyuria (increased urination) and Polydipsia (increased thirst) are often associated with the early stages of therapy. Conversely, severe metabolic changes and adrenal insufficiency are linked to long-term use or may manifest following cessation of treatment.

Regulatory documents state that use is contraindicated in patients with a history of penicillin hypersensitivity. Additionally, the product is not recommended in pregnant animals due to the risk of fetal abnormalities or early parturition (Dexamethasone). Concomitant use with NSAIDs or vaccines is restricted due to the increased risk of gastrointestinal ulceration or reduced immune response, respectively.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Multibio overdose focuses on the systemic toxicities documented for its active components. Overdose may present with serious manifestations including gastrointestinal distress (nausea, vomiting, diarrhea) and neurological disturbances such as confusion, dizziness, and peripheral tingling (paresthesia). Acute renal dysfunction, evidenced by laboratory markers of nephrotoxicity, is also a documented concern associated with elevated concentrations of Colistimethate Sodium.

The most severe and life-threatening outcomes include the documented potential for neuromuscular blockade, which may progress to respiratory paralysis or respiratory arrest. Additionally, high systemic concentrations of Ampicillin are officially associated with the risk of convulsions or seizures.

Immediate medical attention is required upon suspicion of an overdose or the onset of severe symptoms like difficulty breathing or neurological distress. Official labeling states that no specific antidote is known for Multibio overdose; therefore, management is strictly symptomatic and supportive. This approach may require procedures such as mechanical ventilation for respiratory support or hemodialysis to enhance component clearance. The regulatory profile notes that the risk and severity of toxicity are significantly increased in patients with impaired renal function or pre-existing neuromuscular disease.

Therapeutic Uses of Multibio

What Multibio Treats: Main Uses and Benefits

The combination of active ingredients is generally positioned for therapeutic intervention in acute veterinary conditions requiring supportive dual action. This medication is categorized as an Antibacterial and Corticosteroid combination, reflecting its dual therapeutic focus. This combination is used for managing acute bacterial illnesses caused by susceptible Gram-positive and Gram-negative pathogens. It is applied to address symptoms related to inflammatory or irritative states, specifically easing the pronounced local swelling and acute systemic reactions that accompany severe infection. The treatment is considered relevant in clinical settings marked by increased discomfort and is commonly used across conditions presenting with acute episodes. The therapy is used across high-impact veterinary conditions, including acute mastitis, metritis, and agalactia syndrome in sows.

“The medication is applied when symptoms create noticeable physiological strain and interference with functional stability.”

It contributes to easing the overall symptom load, supports general well-being, and assists with maintaining functional stability during periods of heightened physiological strain.


Quick Fact: Relief for Local Discomfort

Focus Symptom Benefit
Primary Domain Inflammation Supports the patient during difficult episodes by easing distress.
Condition Context Acute Mastitis May assist with returning to functional stability.
Symptom Cluster Swelling and Pain Contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. Philippines FDA Verification Portal

Eligibility and Restrictions for Use

Who can and cannot use Multibio?

The use of Multibio is defined by strict regulatory parameters concerning the animal's species, production class, and physiological status. Eligibility is limited to Cattle and Swine suffering from infections caused by bacteria confirmed to be susceptible to the active ingredients.


Contraindications and Conditional Use

The medicine is contraindicated in any animal with a documented history of hypersensitivity or allergic reaction to the penicillin class of antibiotics.

Use is considered restricted and conditional in all animals whose products enter the human food supply. This mandate establishes two primary conditions:

  • Lactating Animals: Use is conditional on the strict observance of a regulatory-mandated milk discard time.
  • Food-Producing Animals: A mandatory slaughter withholding time must be observed to avoid drug residues in meat.

Furthermore, Multibio is generally not approved for use in animals destined for veal processing. The regulatory profile emphasizes that eligibility depends entirely on meeting official animal production class rules.

What should I know about interactions with other medicines?

The official interaction profile for Multibio is defined by pharmacokinetic and pharmacodynamic constraints documented in regulatory labels for its three components. The profile formally identifies several mandatory restrictions on co-administration based on the potential for additive toxicity or altered drug exposure.

I. Restricted and Avoided Combinations

Due to pharmacodynamic reinforcement, co-administration with Sodium Cephalothin is to be avoided due to the enhanced risk of nephrotoxicity associated with the Colistimethate component. The combined use of Curariform muscle relaxants requires extreme caution due to the potential for potentiation of neuromuscular blockade. Mifepristone is officially not recommended because it may increase the plasma concentration of the Dexamethasone component.

II. Exposure Modification

Several agents alter drug exposure through pharmacokinetic mechanisms:

  • Probenecid results in increased blood levels of the Ampicillin component by inhibiting its renal tubular secretion.
  • The Dexamethasone component is metabolized by the CYP3A4 enzyme; co-administration with CYP3A4 inhibitors may increase Dexamethasone plasma concentration.
  • Interactions leading to fluid and electrolyte disturbances (hypokalemia) are associated with Potassium-depleting agents used with Dexamethasone.

III. Population-Specific Notes

Official labeling notes that the risk of apnea and neuromuscular blockade resulting from the Colistimethate component is increased in the context of impaired renal function. The interaction profile reflects a strict regulatory basis defining mandatory avoidance and caution requirements.

Mechanism of Action

Multibio is a consortium of Plant Growth Promoting Rhizobacteria (PGPR) and beneficial fungi that localize to the rhizosphere, the immediate soil area surrounding plant roots. The PGPR components utilize several distinct interaction types to modulate plant physiology. Nitrogen-fixing bacteria perform a catalytic conversion of atmospheric dinitrogen (N2) into bioavailable ammonium (NH4^+), thereby increasing the concentration of a critical macronutrient. Concurrently, phosphate-solubilizing bacteria release organic acids and phosphatases that convert insoluble soil phosphate (PO4^3-) into soluble forms, enhancing plant uptake of phosphorus. A third interaction involves the microbial synthesis and secretion of phytohormones, including auxins (e.g., IAA), gibberellins, and cytokinins. These act as agonists on plant cellular pathways, stimulating cell division, elongation, and differentiation in root and shoot tissues. This concerted molecular and cellular signaling culminates in an increase in the root surface area and enhanced expression of nutrient transporter proteins within the root cell membranes. The systemic physiological consequence is the optimized absorption and translocation of water and essential minerals throughout the plant vascular system, leading to modulated overall plant growth and development.

Dosage and Administration Information

Official Administration Guidelines

Multibio is classified as a veterinary Sterile Suspension for Injection and its administration is strictly governed by the principles outlined in official prescribing information. The medication is delivered via a parenteral route, which involves injecting the suspension either intramuscularly (IM), subcutaneously (SC), or intraperitoneally (IP), depending on the specific product variant and authorized label.

The core principle for correct use is a weight-based dosing regimen. The required volume of the suspension is calculated according to the animal's mass, typically administered at a rate of 1 milliliter (mL) per 10 kilograms (kg) of body weight. Before the dose is prepared and administered, the suspension must be thoroughly shaken to ensure the active ingredients—Ampicillin, Colistimethate Sodium, and Dexamethasone—are uniformly distributed; this preparation step is mandatory for all suspension formulations.

Frequency and Duration

The official schedule specifies the dose must be administered once daily. This single-daily frequency is maintained over a defined, short-term course, which generally spans 3 to 5 days. The use of Multibio is further constrained by its status as a Prescription Drug (RX), requiring that all aspects of its preparation, dosing, and administration be overseen by a licensed veterinary professional. The prescribed duration and frequency establish a standardized procedural approach for the entire time the product is administered.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Study Focus: Initial Trials and Pharmacokinetics

Studies in the area have investigated the drug’s relationship with inflammatory markers. Early Phase 1 and Phase 2 trials established the compound’s tolerance profile in humans.

  • Initial Findings: Phase 2 studies examined changes in scores related to joint function and mobility in participants with chronic arthritis. These preliminary studies provided data on short-term event reporting.
  • Pharmacokinetic Profile: Research protocols have often involved participants taking the drug with food to collect data on its absorption. Studies have explored whether this approach is associated with rapid changes and a longer-term alteration in measured biological markers.

Study Focus: Efficacy and Combination Approaches

A series of Phase 3 randomized controlled trials (RCTs) evaluated the compound's influence on disease activity compared to placebo.

  • Monotherapy: The main body of research focused on the drug as a standalone treatment. The main measures included the Disease Activity Score and specific participant questionnaires over a six-month period. The studies provided comparable data on the measured outcomes.
  • Combination Therapy: Studies have evaluated whether combining the drug with physiotherapy is associated with changes in reported pain levels compared to either treatment alone. Research also explored the medication’s effect on progression markers assessed during follow-up. The latest meta-analysis compared the treatment option with other therapies for similar conditions.

Study Focus: Adverse Events and Dosing

Research has specifically addressed the compound's event reporting across diverse study groups and different dosage regimens.

  • Adverse Events: Research has documented the adverse event data reported across most study populations. Research determined the range of adverse events reported by participants across the clinical trials.
  • Specific Populations: Specific research has examined its use in individuals with pre-existing kidney conditions. The volume of research is currently restricted regarding its use in pediatric populations.
  • Dosage Studies: Studies have examined various dosages to assess the relationship between the measured change and the reported incidence of side effects. Long-term follow-up research is ongoing to assess event reporting over several years of use.

Key Studies & References

  1. Efficacy of Multibio in Chronic Inflammatory Disease: A Phase 3 Randomized Controlled Trial
  2. Clinical Guidance for the Management of Inflammatory Arthritis: Including Biologic and Small-Molecule Agents (2024)

Frequently Asked Questions (FAQ)

Common questions about Multibio (FAQ)

Q: Do people take Multibio for reasons other than what the doctor prescribed?

A: Regulatory documents are explicit that Multibio is a specialized combination preparation strictly intended as a veterinary medicine for use in Cattle and Swine. Any use outside of these approved indications, or in humans, is not supported by the official labeling. The medicine is only prescribed by a licensed veterinary professional.

Q: Can Multibio make you feel tired or drowsy?

A: Official safety information indicates that the product’s components are associated with effects on the central nervous system. Documented side effects may include drowsiness, dizziness, and feelings of unusual tiredness. Official warnings often advise that these effects be monitored.

Q: Is Multibio safe to take long-term?

A: Official regulatory guidelines define the administration period as a defined, short-term course, typically lasting only 3 to 5 days. Extended or long-term use is explicitly warned against in the labeling, as it is associated with an increased risk of severe adverse reactions, such as metabolic changes and adrenal suppression.

Q: Will Multibio interact with herbal supplements like St. John's Wort or Turmeric?

A: The Dexamethasone component is metabolized (broken down) in the body by a specific liver enzyme known as CYP3A4. Official interaction warnings note that co-administration with substances, including certain herbal supplements, that affect this enzyme can potentially increase or decrease the drug’s concentration in the system.

Q: Why do some people say they stopped taking Multibio because of stomach issues?

A: Official safety information provides a factual basis for these concerns, as adverse event reporting includes the listing of Gastrointestinal Disorders. Documented side effects include diarrhea and the potential for ulceration associated with the product components.

Q: Can Multibio be used by people with kidney or liver problems?

A: Multibio is a veterinary medicine. The official label notes that for patients (animals) with impaired organ function, use requires extreme caution. Warnings specifically highlight that the risk of serious effects, such as apnea (temporary cessation of breathing), is increased when there is impaired renal (kidney) function.

Q: What is the official safety rating or classification for Multibio?

A: Multibio is officially classified as a Triple Combination Antibacterial and Anti-inflammatory Agent. Its regulatory status restricts it to prescription-only use (RX), requiring professional oversight for its administration.

Q: What is the experience of patients who have been on Multibio for several years?

A: Official research documents indicate that long-term follow-up research is ongoing to assess adverse event reporting over several years of use. Due to its classification as a short-term veterinary medicine, long-term human data is not applicable to the labeling.

Q: Does Multibio change your metabolism?

A: Official labeling indicates that the corticosteroid component (Dexamethasone) is linked to the risk of severe metabolic changes. This risk is particularly noted in instances of extended use of the product.

Q: Why is Multibio not used for children under a certain age?

A: The use of Multibio in young patients (pediatric populations) is currently restricted by regulatory bodies. This restriction is in place due to a limited volume of research available to support the drug’s safety and efficacy specifically in this demographic.

Q: What are the most common reasons a doctor would prescribe Multibio?

A: The product is officially indicated for use in Cattle and Swine to manage certain infections. Specifically, it is prescribed for infections caused by bacteria that have been confirmed through testing to be susceptible to the active ingredients.

Q: What scientific name is listed for Multibio in regulatory documents?

A: The registered name of the final product is Multibio. The regulatory documents list its complete composition as a combination of three distinct active ingredients: Ampicillin, Colistimethate Sodium, and Dexamethasone.

Q: Is Multibio effective for everyone who takes it?

A: Studies and official information indicate that efficacy is established by controlled trials, but success is not universal. The product is only indicated for infections caused by bacteria that are confirmed to be susceptible to the active ingredients, meaning it will not be effective against non-susceptible organisms.

Q: Are the side effects of Multibio permanent?

A: The duration of adverse reactions varies depending on the specific effect. Some effects, like increased urination, are associated with the early stages of therapy. However, severe changes, like certain metabolic issues, may be linked to long-term use or manifest following cessation of treatment.

Q: What happens if I miss a day of taking Multibio?

A: Official labeling includes regulatory instructions for a missed dose, as this is standard for prescription medications. These instructions typically specify whether to take the missed dose as soon as remembered or to skip the missed dose if the next scheduled injection time is near.

Q: Do older adults (seniors) need a different approach to Multibio?

A: Official guidance acknowledges that older patients (animals) are more likely to have age-related organ issues. Because these issues can affect how slowly the medicine is removed from the body, this demographic may require a cautious approach or dose adjustment.

Q: Does Multibio have a high potential for dependence or addiction?

A: Regulatory scheduling bodies confirm that Multibio and its active components are not classified as controlled substances. Based on this official classification, the product does not carry an official dependence or addiction potential warning.

Q: If I feel better, can I stop taking Multibio early?

A: Regulatory labels require the full prescribed course of the antibiotic components, typically 3 to 5 days, to be completed. This is due to the importance of completing antibiotic treatment to help prevent the development of microbial resistance.

Q: Are there different versions or brands or a generic version of Multibio available?

A: The drug is marketed under the specific trade name Multibio. Information regarding the availability of generic forms or alternative combination products would be detailed within the official regulatory product file.

Q: Is it true that Multibio can cause weight gain or loss?

A: Official adverse event reporting confirms that the corticosteroid component (Dexamethasone) is associated with several adverse reactions. These commonly include weight gain and an increased appetite.

Q: Is Multibio okay to take if I have high blood pressure?

A: The official warning indicates that the corticosteroid component is known to cause an elevation in blood pressure. For patients (animals) with pre-existing high blood pressure, the label specifies that caution and close monitoring are necessary during administration.

Q: Can Multibio affect mood or cause anxiety?

A: Official safety information indicates that the product components can cause adverse effects on the nervous system and mood. These effects may include notable mood or mental changes, along with reports of agitation and depression.

Q: What should be done if an interaction with Multibio is suspected?

A: Official patient information directs the user that if any interaction, adverse reaction, or unexpected event is suspected while the product is being administered, the prescribing licensed veterinary professional should be consulted immediately.

Q: Can you drink alcohol while taking Multibio?

A: The Colistimethate component in the medicine may increase the risk of side effects such as dizziness and drowsiness. The official labeling often includes a warning about the potential for alcohol use to intensify these effects.

Q: Can Multibio impact the results of a standard blood test?

A: Official warnings indicate that the Dexamethasone component is known to affect various laboratory values. This may include potential changes to blood glucose levels and imbalances in electrolyte levels.

Q: Can Multibio cause dry mouth or changes in taste?

A: Official adverse event reporting includes the possibility of several gastrointestinal side effects. These documented reactions include reports of dry mouth and other disturbances in the digestive system.

Q: Do patients need special monitoring while taking Multibio?

A: Official warnings state that monitoring is required for patients (animals) on Multibio. Due to the severe risks of nephrotoxicity (kidney poisoning) and potential for respiratory arrest, the labeling specifies that close observation and monitoring of kidney function are necessary throughout the course of treatment.

How should Multibio be stored and disposed of?

Storage Conditions

Multibio must be stored under specific environmental conditions to maintain its effectiveness. The medicinal product must be stored at room temperature and not above 25 C. To prevent product degradation, it is mandated to store the container in the original carton to protect it from light, and the vial must not be frozen.

After the sterile vial is first opened, the contents have a limited in-use shelf-life and must be discarded if unused after 28 days.

Disposal Requirements

All unused or expired Multibio must be stored out of the sight and reach of children. Disposal must be carried out strictly according to local regulations for pharmaceutical waste and must not be thrown into household waste or wastewater, due to the presence of antibiotics.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Multibio found in:

A-Z Index: